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Abstract
Background: We characterized the biologic effects of a novel small molecule STAT3 pathway inhibitor that is derived 
from the natural product curcumin. We hypothesized this lead compound would specifically inhibit the STAT3 
signaling pathway to induce apoptosis in melanoma cells.
Results: FLLL32 specifically reduced STAT3 phosphorylation at Tyr705 (pSTAT3) and induced apoptosis at micromolar 
amounts in human melanoma cell lines and primary melanoma cultures as determined by annexin V/propidium 
iodide staining and immunoblot analysis. FLLL32 treatment reduced expression of STAT3-target genes, induced 
caspase-dependent apoptosis, and reduced mitochondrial membrane potential. FLLL32 displayed specificity for STAT3 
over other homologous STAT proteins. In contrast to other STAT3 pathway inhibitors (WP1066, JSI-124, Stattic), FLLL32 
did not abrogate IFN-γ-induced pSTAT1 or downstream STAT1-mediated gene expression as determined by Real Time 
PCR. In addition, FLLL32 did not adversely affect the function or viability of immune cells from normal donors. In 
peripheral blood mononuclear cells (PBMCs), FLLL32 inhibited IL-6-induced pSTAT3 but did not reduce signaling in 
response to immunostimulatory cytokines (IFN-γ, IL 2). Treatment of PBMCs or natural killer (NK) cells with FLLL32 also 
did not decrease viability or granzyme b and IFN-γ production when cultured with K562 targets as compared to vehicle 
(DMSO).
Conclusions: These data suggest that FLLL32 represents a lead compound that could serve as a platform for further 
optimization to develop improved STAT3 specific inhibitors for melanoma therapy.
Background
Malignant melanoma is the most deadly form of skin can-
cer, and its incidence is rising faster than that of any other
cancer. The prognosis for patients with metastatic disease
is poor, and even the most effective therapies produce an
overall response rate of only 10-15%. Therefore, novel
approaches for treating this disease are urgently needed.
Activation of signal transducer and activator of tran-
scription-3 (STAT3) in melanoma tumors is associated
with poor prognosis [1-3]. This transcription factor can
promote cell proliferation and angiogenesis, inhibit apop-
tosis, and drive invasion and metastasis [1-3]. Constitu-
tive STAT3 phosphorylation is mediated by several
upstream kinases (e.g. Jak2, Src) and is thought to be a
key component of the oncogenic process [4,5]. Despite its
necessity in early embryogenesis, STAT3 appears to be
largely dispensable in most normal adult cell and tissue
types [6,7]. These data suggest that STAT3 inhibition rep-
resents a rational approach to therapy for this disease.
Emerging data suggest that natural products may repre-
sent effective candidate molecules for drug discovery.
Curcumin, 1,7-bis(4-hydroxy-3methoxyphenyl)-1,6-hep-
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Page 2 of 12tadien-3,5-dione, is one such candidate [8] based on its
chemopreventative and therapeutic properties in experi-
mental models including melanoma and its ability to
inhibit a variety of targets including STAT3 [9-11].
Administration of curcumin has been shown to be safe in
humans [12,13], however its clinical utility is somewhat
limited due to the poor bioavailability and target selectiv-
ity. The lack of selectivity is due to the numerous molecu-
lar targets with which curcumin is known to interact.
Therefore, efforts are underway by our group and others
to design and synthesize novel curcumin analogs to focus
its inhibitory activity toward the STAT3 pathway [14].
Indeed prior studies by our group have shown that
despite its direct pro-apoptotic effects on human mela-
noma cells, curcumin inhibits the cellular response to
clinically relevant cytokines [15]. These data suggest that
structural analogs of curcumin which retain the ability to
inhibit the STAT3 oncogenic signaling pathways while
leaving the STAT1 tumor suppressor pathway, and
immune effector function intact could be most useful for
cancer therapy.
The molecular structure of curcumin indicates that the
molecule exists in two distinct tautomeric forms: 1) a
diketone form and 2) a keto-enol form, which each have
unique properties relevant for drug design (Figure 1A).
We developed a series of analogs based on curcumin in
its diketone form which were predicted by computational
modeling to interact with the SH2 domain of STAT3 [16]
and inhibit STAT3 homodimerization (unpublished
observations, Dr. Pui-Kai Li, The Ohio State University).
One analog, termed FLLL32, was selected as a candidate
for inhibition of the Jak2-STAT3 pathway (Figure 1A).
This analog has previously been shown to inhibit the
Jak2-STAT3 pathway and elicit anti-tumor activity
against pancreatic and breast cancer cells [16].
In the present report we have characterized the biologic
activity of the FLLL32 curcumin analog on human mela-
noma and immune effector cells. Our data indicate that
FLLL32 can inhibit STAT3 phosphorylation and promote
caspase-dependent apoptosis of human melanoma cells
at concentrations 10-fold lower than curcumin [15].
FLLL32 displayed a greater specificity for STAT3 than
curcumin or other comparable inhibitors. This com-
pound did appear to alter the activation of other structur-
ally similar STAT proteins, as interferon-induced STAT1
signaling and gene expression were intact in the presence
of FLLL32. Treatment of PBMCs with FLLL32 also elimi-
nated basal and IL-6 induced pSTAT3. In contrast,
FLLL32 did not adversely affect the response of PBMCs
to stimulation with IFN-γ and IL 2 or the viability and
cytotoxicity of NK cells. These data suggest that FLLL32
represents a promising lead compound that can be opti-
mized further for development as a therapeutic agent in
melanoma.
Materials and methods
Cell Culture and Reagents
A375, HT144 and Hs294T human melanoma, and the
K562 leukemia cell lines were purchased from the Ameri-
can Type Culture Collection (ATCC, Manassas, VA) and
1106 MEL, 1259 MEL, MEL-39 and F01 human mela-
noma cell lines were provided by Dr. Soldano Ferrone
(University of Pittsburgh, Pittsburgh, PA) and cultured as
described [17]. Melanoma cell lines were authenticated
via karyotype analysis in the Molecular Cytogenetics
Core Laboratory of The Ohio State University. The radial
growth phase WM 1552c and vertical growth phase WM
793b human melanoma cell lines were provided by Dr. M.
Herlyn (Wistar Institute, Philadelphia, PA) and cultured
as described [18]. Primary cultures from patients with
recurrent cutaneous melanomas were cultured as previ-
ously described [17]. Tetramethylrhodamine ethyl ester
perchlorate (TMRE) was purchased from Invitrogen
(Carlsbad, CA). The pan-caspase inhibitor (Z VAD-
FMK), control (Z-FA-FMK) and recombinant human
IFN-γ were purchased from R & D Systems, Inc. (Minne-
apolis, MN). Recombinant human interleukin-6 (IL 6)
was purchased from Peprotech, Inc. (Rocky Hill, NJ).
Recombinant human IL-2 (specific activity = 107 U/mg)
was purchased from Hoffmann-La Roche Pharmaceuti-
cals (Nutley, NJ). The JSI-124 and Stattic inhibitors were
purchased from Calbiochem (Gibbstown, NJ). WP1066
was synthesized in the laboratory of Dr. P-K Li [19].
FLLL32 and curcumin were synthesized, purified and
evaluated for purity as previously described [16,20,21].
Peripheral Blood Mononuclear Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from source leukocytes of healthy donors (Ameri-
can Red Cross, Columbus, OH) via density gradient
centrifugation using Ficoll-Paque (Amersham, Pharmacia
Biotech, Bjorkgatan, Sweeden) as described [22]. NK cells
were enriched from source leukocytes by negative selec-
tion with Rosette Sep reagents (Stem Cell Technologies,
Inc., Vancouver, British Columbia, Canada).
Immunoblot Analysis
Lysates were prepared from melanoma cell lines or
PBMCs and assayed for protein expression by immunob-
lot analysis as previously described with antibodies (Ab)
to STAT1 (BD Biosciences), Survivin (Novus Biologicals,
Littleton, CO), pSTAT1, STAT3, pSTAT3, pSTAT5,
STAT5, pJAK2, JAK2, PARP, Cyclin D1, Caspase-3, Cas-
pase-8, Caspase-9, phosphorylated and total Akt (pAkt),
Src (pSrc), p38 MAPK (p-p38 MAPK), ERK (pERK) (Cell
Signaling Technology, Danvers, MA), or β-actin (Sigma)
[23]. Following incubation with the appropriate horserad-
ish-peroxidase-conjugated secondary Ab, immune com-
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Figure 1 The FLLL32 curcumin analog induced apoptosis in human melanoma cells. (A) The molecular structure of curcumin indicates that the 
molecule exists in two distinct tautomeric forms: 1) a diketone form and 2) a keto-enol form. FLLL32 was designed as a novel structural analog of cur-
cumin that approximates a modified version of the molecule when locked into the keto-form. (B) Annexin V/PI staining of human metastatic melano-
ma cells following a 48 hour treatment with FLLL32. Error bars show 95% prediction limits based on the model fit at the estimated IC50 from two or 
more independent experiments. The non-responsive 1106 MEL and 1259 MEL cell lines were pSTAT3-negative. (C) Annexin V/PI staining of represen-
tative pSTAT3+ melanoma cells treated with either 20 μM curcumin or 2 μM FLLL32. Data are presented as the mean percentage of apoptotic cells. 
Error bars represent the standard deviation from at least two individual experiments. (D) Immunoblot analysis (left panel) or immunoprecipitation for 
total Jak2 protein (right panel; blot with Jak2 or pJak2 antibodies) of pSTAT3-positive A375 and Hs294T cells following 24 hour treatment. (E) FLLL32 
treatment reduced pSTAT3, the STAT3-regulated gene, cyclin D1 and induced apoptosis in primary human cells derived from recurrent cutaneous 
melanoma tumors. These primary melanoma cell cultures have been previously described by our group [17]. Cells were treated for 48 hours with the 
indicated concentrations of FLLL32 or curcumin (20 mM) as a biologic control and analyzed by immunoblot. Membranes were probed with β actin 
as a loading control and all blots represent data from at least two independent experiments.
A B
0
10
20
30
40
50
60
70
80
90
100
A375 Hs294T FO1
Cell Line
%
 A
p
o
p
to
si
s
Curcumin (20 uM)
FLLL32 (2 uM)
C
pJAK2
FLLL32 (M):
A375 Hs294T
0   2   4  6   8 0  2   4  6  8
JAK2
PARP
p705STAT3
FLLL32 (M):
-Actin
STAT3
pERK
pSrc
Src
ERK
p-p38 MAPK
p38 MAPK
pAkt
Akt
A375 Hs294T
0    2     4 0    2     4
p727STAT3
D
0   2    4    6    8  Cur
PARP
pSTAT3
STAT3
Cyclin D1
-Actin
0    2   4   6    8  Cur
Patient 1 Patient 2
FLLL32 (M):
E
pSTAT3neg
pSTAT3+
FLLL32 (M)
O O
OCH3CH3O
HO OH
H
O O
OCH3CH3O
HO OHDiketone form keto-enol formCurcumin
diketone tautomer
Curcumin
keto-enol tautomer
Tautomerization
FLLL32 is “locked”
into diketone
tautomeric form
O O
MeO
MeO
OMe
OMe
FLLL32
lead compound
Bill et al. Molecular Cancer 2010, 9:165
http://www.molecular-cancer.com/content/9/1/165
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Chemiluminescent Substrate (Thermo Fisher Scientific).
Annexin V/Propidium Iodide Staining
Phosphatidyl serine exposure was assessed in tumor cells
by flow cytometry using APC-Annexin V and propidium
iodide (PI; BD Pharmingen, San Diego, CA) as described
[23]. Analyses were performed utilizing at least 10,000
events.
STAT3 DNA binding assays
STAT3 DNA binding was measured with the Pierce
LightShift Chemiluminescent EMSA kit used according
to manufacturer's instructions (Thermo Fisher Scientific
Inc, Rockford, IL). Nuclear protein was collected using
the NucBuster™ Protein Extraction kit (EMD Chemicals
Inc, Gibbstown, NJ). Binding reactions using equal
amounts of nuclear protein were incubated for 20 min-
utes at room temperature with DNA probes. A biotiny-
lated STAT3 binding sequence in the human survivin
promoter (sense 5'-GAGACTCAGTTTCAAATAAATA
AATAAAC-3') was purchased from Operon Biotechnolo-
gies (Huntsville, AL). Reactions with biotinylated target
DNA only and nuclear protein with biotinylated target
DNA and excess unlabelled target DNA to compete for
binding were included. STAT3 specificity was confirmed
by incubation with 6μg of anti-STAT3 Ab (Santa Cruz
Biotechnology Inc, Santa Cruz, CA) to interfere with the
protein-DNA complex. Following electrophoresis, DNA
was transferred to a nylon membrane, cross-linked and
detected by chemiluminescence.
Flow Cytometric Assay of Mitochondrial Membrane 
Potential
The mitochondrial membrane potential (ΔΨm) was
assayed using 150 nM TMRE in regular medium at 37ºC
for 15 minutes and by subsequent flow cytometric analy-
sis as described [24].
Real Time PCR
Real-time PCR was used to evaluate the expression of the
IFN-γ stimulated gene (IRF1) as described [25,26] with
pre-designed primer/probe sets (Assays On Demand;
Applied Biosystems, Foster City, CA) and 2X TaqMan
Universal PCR Master Mix (Applied Biosystems) per
manufacturer's recommendations. Primer/probe sets for
18s rRNA (Applied Biosystems) were used to normalize
expression values (housekeeping gene). Data were
acquired and analyzed using the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems).
ELISPOT Assay for Granzyme B and IFN-γ
To measure granzyme B (GrB) and IFN-γ secretion,
ELISPOT experiments were conducted using Multi-
Screen 96-well plates (Millipore, Bedford, MA) and bioti-
nylated monoclonal anti-human GrB or IFN-γ detecting
Ab (Mabtech) as described [27]. Freshly isolated NK cells
(effectors) were incubated overnight in IL-2-containing
media (1 nM) with either 5μM FLLL32 or DMSO. Effec-
tor cells were then co-incubated in triplicate with K562
cells as targets at an effector:target ratio of 10:1 for four
hours. Targets and effectors cultured alone were used as
controls. Spots were visualized and counted using the
ImmunoSpot Imaging Analyzer (Cellular Technology
Ltd, Cleveland, OH).
Statistical Analysis
The 4-parameter logistic or Hill model [28] was the
assumed dose-response relationship for FLLL32 concen-
tration and proportion of apoptotic cells. Nonlinear least
squares regression was used to estimate the parameters.
ELISPOT data were compared between groups using a
two-sample t-test. All analyses were performed in Statis-
tical Analysis System (version 9.2; SAS Institute). P-val-
ues were considered significant at the 0.05 level and all
tests were two-sided.
Results
FLLL32 induces apoptosis in human melanoma cell lines
The pro-apoptotic effects of FLLL32 (Figure 1A) were
examined by flow cytometry following Annexin V/PI
staining of a panel of metastatic human melanoma cell
lines with basal STAT3 phosphorylation (A375, Hs294T,
FO1, HT144, MEL-39) and the pSTAT3 negative 1106
MEL and 1259 MEL cell lines [17]. Dose-response studies
revealed consistent induction of apoptosis in pSTAT3-
positive metastatic human melanoma cell lines following
a 48 hour treatment with FLLL32 as compared to DMSO
(vehicle) treated cells (Figure 1B). The pSTAT3-positive
A375 cell line was particularly sensitive to the pro-apop-
totic effects of FLLL32 (IC50 = 1.3μM at 48 hours). Similar
data were obtained in multiple pSTAT3 positive human
melanoma cell lines (IC50 range = 1.9 -- 2.8 at 48 hours).
The pSTAT3 negative 1106 MEL and 1259 MEL cell lines
were poorly sensitive to FLLL32 (Figure 1B). FLLL32 was
more potent than curcumin at inducing apoptosis (Figure
1C). Consistent with prior studies from our group, a 10-
fold greater concentration of curcumin was required to
achieve the same degree of apoptosis at the 48 hour time
point [15]. FLLL32-induced apoptosis was also confirmed
in pSTAT3+ human melanoma cell lines derived from
other disease phenotypes, including the WM 1552c radial
growth phase and WM 793b vertical growth phase lines
following treatment with FLLL32 (data not shown).
FLLL32 inhibits STAT3 phosphorylation and gene 
expression in human melanoma cell lines
FLLL32 inhibited STAT3 phosphorylation at Tyr705 but
not at Tyr727 in multiple human melanoma cell lines after
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FLLL32 could inhibit Jak2 kinase activity in an in vitro
cell-free assay [16]. However, we did not observe an
appreciable alteration in Jak2 phosphorylation even at a
concentration of 8 μM, suggesting that this compound
likely acted directly against the STAT3 protein (Figure
1D). Time course studies also revealed that fulminant cell
death occurred after 24 hours of continuous culture, yet
exposure to FLLL32 at 2 - 4 μM for only 4 hours was suf-
ficient to reduce pSTAT3 and induce cell death (Addi-
tional File 1: Figure S1A-B). FLLL32 did not appear to
inhibit the phosphorylation of other key signaling path-
ways that are constitutively active in malignant cells (e.g.
Src, Akt) at doses capable of inhibiting STAT3 phospho-
rylation after 24 hours. Consistent with reciprocal activa-
tion of the p38 MAPK and STAT3 pathways [29], FLLL32
treatment led to increased levels of total p38 MAPK pro-
tein once pSTAT3 decreased (Figure 1D). Importantly,
FLLL32 was capable of reducing pSTAT3 levels, cyclin
D1 expression and inducing apoptosis in primary human
melanoma cell cultures derived from recurrent cutaneous
melanoma tumors [17] (Figure 1E). Finally, treatment of
basal pSTAT3-positive human melanoma cell lines with
FLLL32 for 24 hours led to reduced STAT3 DNA binding
as determined by gel shift assays and expression of the
STAT3-regulated genes, cyclin D1 and survivin as mea-
sured by immunoblot (Figure 2A-B).
FLLL32 induced cell death is caspase-dependent
The mechanism by which FLLL32 induces apoptosis was
subsequently investigated in the A375 melanoma cell line.
Immunoblot analysis demonstrated a concentration-
dependent increase in the processing of both initiator
(caspase-8 and caspase-9) and effector caspases (caspase-
3) following a 24 hour treatment with FLLL32 (Figure
3A). Treatment of with FLLL32 also resulted in a concen-
tration-dependent loss of mitochondrial membrane
potential as measured by flow cytometry (Figure 3B).
These data support the involvement of the mitochondrial
amplification loop in promoting cell death in response to
this treatment. Apoptosis was caspase-dependent, as cul-
ture with a pan-caspase inhibitor (Z-VAD-FMK) inhib-
ited melanoma cell death as compared to culture with the
Z-FA-FMK control compound (Figure 3C and Additional
File 1: Figure S2). These data were confirmed at the 48
hour time point by flow cytometry following annexin V/
PI staining, and by reduced PARP cleavage by immunob-
lot analysis (Figure 3C-D). Interestingly, reduced levels of
pSTAT3 and cyclin D1 occurred following treatment of
A375 cells with FLLL32 in the presence of the pan-cas-
pase inhibitor (Figure 3D). These data are consistent with
a mechanism that places reduced pSTAT3 and its cellular
targets upstream of the caspase cascade and subsequent
apoptosis.
IFN-γ induced STAT1 signaling and gene expression are not 
inhibited by FLLL32
Since many cytokines act via homologous STAT proteins
(e.g. STAT1), it was imperative to test whether FLLL32
had deleterious effects on the action of cytokines that
might promote an anti-tumor response. Of concern were
the effects of FLLL32 on signal transduction in response
to IFN γ, a cytokine that mediates its cellular effects via
phosphorylation of STAT1, and a resulting STAT1-
STAT1 homodimer [25]. To test these interactions in a
biologic system, we investigated the effects of FLLL32 or
curcumin pre-treatment on IFN-γ-induced signaling and
gene expression. Pre treatment of pSTAT3 positive A375
and Hs294T cells with FLLL32 or curcumin led to
reduced pSTAT3 versus DMSO-treated cells. However, in
contrast to curcumin, FLLL32 did not adversely affect
IFN-γ-induced pSTAT1 (Figure 4A and Additional File 1:
Figure S3). A unique advantage of FLLL32 versus other
STAT3 pathway inhibitors was its apparent specificity.
Despite a similar degree of cytotoxicity and the ability to
reduce basal pSTAT3 in human melanoma cells (Addi-
tional File 1: Figure S4), the WP1066, JSI-124, and Stattic
compounds also inhibited IFN-γ-induced STAT1 phos-
phorylation (Figure 4B). Pre-treatment with FLLL32 also
enhanced transcription of the pro-apoptotic interferon-
regulatory factor-1 (IRF1) gene in response to IFN-γ
stimulation as determined by Real Time PCR (Figure 4C).
This IFN-γ responsive gene has been shown to be tran-
scribed via STAT1-STAT1 homodimers binding to a
gamma-activated sequence (GAS) element [25]. Consis-
tent with our prior studies [15], IFN-γ stimulated IRF1
transcription was reduced in all cells pre-treated with
curcumin (Figure 4C). The induction of IRF1 was not
enhanced in the pSTAT3 negative 1106 MEL cell line
(Figure 4C), suggesting that cross-reactivity of FLLL32
with STAT1 was negligible, and that IFN-γ driven gene
transcription can be augmented via STAT3 inhibition.
These data indicated that IFN-γ-induced signal transduc-
tion and gene expression were not reduced by FLLL32
and that its inhibitory actions were specific for STAT3
and not other homologous STAT proteins that function
as tumor suppressors (e.g. STAT1) [30-33].
Effects of FLLL32 on immune effector cells
STAT3 function in immune cells can promote tolerance
to developing or established tumors. We therefore evalu-
ated whether FLLL32 would affect the responsiveness of
PBMCs to stimulation with clinically relevant cytokines
that mediate tumor progression (IL 6), immunosurveil-
lance (IFN-γ) or T and NK cell survival (IL 2) [34-36]. Pre
treatment with increasing doses of FLLL32 reduced basal
pSTAT3 in PBMCs from healthy donors and led to
reduced IL-6-induced pSTAT3 in PBMCs (Figure 5A).
FLLL32 pre-treatment also did not adversely affect the
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in PBMC (Figure 5B-C). The level of IL 2-induced
pSTAT5 also was not altered by FLLL32 pre-treatment
(Figure 5D). The FLLL32 compound did not decrease via-
bility of PBMCs after a 24 hour treatment as compared to
treatment with DMSO alone as determined by Annexin
V/PI staining or PARP cleavage (Figure 6A-B). Similarly,
NK cell viability from healthy donors cultured with IL-2
(1 nM) was not reduced following a 24 hour treatment
with FLLL32 as compared to treatment with DMSO (Fig-
ure 6C). In addition, the production of granzyme b and
IFN-γ by NK cells from normal donors when cultured
with the K562 target cell line was not adversely affected in
the presence of FLLL32 (Figure 6D). The mean difference
(FLLL32 - DMSO) for granzyme b was 41.0 spots/well
(95% CI: -79.0 to 161.0) and 65 spots/well for IFN-γ (95%
CI: -146.0 to 277.9).
Discussion
We have characterized the biologic activity of the cur-
cumin analog, FLLL32 on melanoma and immune effec-
tor cells. The present study has demonstrated that the
FLLL32 small molecule can inhibit STAT3 signal trans-
duction and induce caspase-dependent, pro-apoptotic
effects against human melanoma cell lines and primary
melanoma cultures at micromolar concentrations. In
contrast to curcumin and other STAT3 pathway inhibi-
tors, IFN-γ-induced STAT1 phosphorylation was not
altered in the presence of FLLL32. This compound did
not inhibit the viability of PBMCs, NK cells or their cellu-
lar responsiveness to clinically relevant cytokines. These
data show that FLLL32 represents a novel small molecule
curcumin analog with STAT3 pathway specificity that
will be considered as a lead compound for further drug
development in melanoma.
FLLL32 represents a structural analog of curcumin
when locked into its diketone tautomeric form. A num-
ber of favorable biologic properties resulting from these
modifications have been characterized in this study. First,
FLLL32 was ten-fold more potent than curcumin at
inducing apoptosis of melanoma cells [15]. Second,
FLLL32 did not appear to have toxic effects on either nor-
Figure 2 FLLL32 reduced STAT3 DNA binding and gene expression. (A) STAT3 DNA binding was measured in A375 cells following a 16 hour treat-
ment with FLLL32 (2 μM or 4 μM) as described in the Methods section. Unlabeled target DNA were included to compete for binding as indicated, and 
a STAT3 specific Ab was used to were included confirm specificity (last lane). Cell lysates were evaluated concurrently by immunoblot to control for 
total level of STAT3 protein at the 16 hour time point. (B) FLLL32 reduced STAT3-regulated gene expression. Expression of STAT3-regulated genes cy-
clin D1 and survivin were evaluated following a 24 hour treatment with FLLL32 in melanoma cell lines. Membranes were probed with β actin as a 
loading control and all blots represent data from at least two independent experiments.
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specifically target the oncogenic STAT3 pathway, while
leaving the STAT1 pathway intact. Data from the present
report indicate that in terms of in vitro specificity,
FLLL32 was superior to other STAT3 pathway inhibitors
or to curcumin. In fact, prior studies from our group have
demonstrated that curcumin inhibited the phosphoryla-
tion of numerous STAT proteins in response to clinically
relevant cytokines including IFN-γ (STAT1), IFN-γ
(STAT1) and IL 2 (STAT5) [15]. These inhibitory effects
of curcumin were observed in both melanoma cell lines
and in PBMCs from healthy donors. As a result, design of
the FLLL32 analog was focused on maximizing the target
specificity for STAT3 over other STAT proteins. The
present data support the STAT3 specificity of the FLLL32
lead compound, although they do not conclusively
exclude that FLLL32 could modulate the phosphorylation
of other unidentified kinases.
Numerous early generation small molecule STAT3
inhibitors (e.g. Stattic, STA-21, LLL12, S32 M2001, S3I-
Figure 3 FLLL32 induced caspase-dependent apoptosis and loss of mitochondrial membrane potential. (A) Processing of caspase proteins 
was measured by immunoblot following a 24 hour treatment of A375 cells with FLLL32. The molecular weight of each pro-caspase and their active 
forms are listed on each blot in kilodaltons (kDa). Data shown are representative of at least two independent experiments. (B) A375 cells were treated 
for 24 hours with FLLL32 and stained with 150 nM TMRE to assay loss of mitochondrial membrane potential (ΔΨm) by flow cytometry. Voltage was set 
using unstained cells (M1). The percentage of cells with reduced ΔΨm is denoted above each histogram. Data are representative of three or more in-
dependent experiments. Flow cytometric analysis of annexin V/PI staining following a 48 hour treatment of (C) A375 cells with FLLL32 in the presence 
of the Z VAD-FMK pan-caspase inhibitor or the Z-FA-FMK control compound. Inhibitors were used at 50μM and the percentage of cells in each quad-
rant are shown. (D) Immunoblot analysis of A375 cells following a 48 hour treatment with FLLL32 cultured in the presence of the Z-VAD-FMK pan 
caspase inhibitor (+) or the Z FA FMK control compound (-). Data shown are representative of two separate experiments with the A375 cell line and 
were also reproducible in the Hs294T cell line (Additional File 1: Figure S2).
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Page 8 of 12201) have been reported to induce apoptosis via inhibi-
tion of STAT3 activation and/or dimerization [33,37],
while siRNA specific for the SH2 coding region of STAT3
could induce apoptosis in prostate cancer cells in vitro
and in nude mice bearing human xenograft tumors [32].
Finally, studies have also shown that platinum complexes
can promote anti-tumor activity by virtue of their ability
to inhibit STAT3 [38]. Collectively, these studies provide
precedent for targeting STAT3 as a means of inducing
tumor cell apoptosis. However, the specificity of many
existing inhibitory strategies for STAT3 and not other
STAT proteins (e.g. STAT1) or oncogenic pathways has
not been validated in biological systems. An attractive
aspect of FLLL32 was its specificity and activity at micro-
molar concentrations. Data from the present study sug-
gest that FLLL32 represents a unique molecule that can
be optimized further for inhibition of the STAT3 path-
way.
STAT3 can promote immune tolerance in the setting of
cancer and thus represents an attractive target to enhance
immunotherapy (Reviewed in [39]). Recent studies from
our group and others have demonstrated that the pres-
ence of constitutively active STAT3 in melanoma cells is
correlated with reduced responsiveness to cytokines
Figure 4 IFN-γ-induced signal transduction was not adversely affected by FLLL32. (A) A375 cells were pre-treated for 16 hours with FLLL32 (2 -
- 14 μM) or curcumin (20 μM) and subsequently treated with IFN-γ (10 ng/mL) for 15 minutes. IFN-γ-induced pSTAT1 and pSTAT3 were evaluated by 
immunoblot. Total STAT1, STAT3 and β-actin were also measured to control for loading. The data were also summarized by densitometry comparing 
relative expression of pSTAT1 to STAT1 and pSTAT3 to STAT3. (B) The same experiment was performed whereby A375 cells were pre-treated for 16 
hours with other Jak2/STAT3 pathway inhibitors (WP1066, JSI-124, Stattic) prior to IFN-γ stimulation. Data shown are representative of two separate 
experiments and similar results were obtained in the Hs294T human melanoma cell line (Additional File 1: Figure S3). (C) IFN-γ-induced gene expres-
sion was enhanced in the presence of FLLL32. A375, Hs294T or 1106 MEL cells were pre-treated for 1 hour with 2μM FLLL32, 20μM curcumin or DMSO 
(negative control), and subsequently stimulated with IFN-γ (10 ng/mL) or PBS (vehicle) for an additional 4 hours. Expression of IRF1 was evaluated by 
Real Time PCR. Data were normalized to 18s rRNA levels (housekeeping gene) and expressed as the mean fold change versus DMSO-pre-treated cells 
stimulated with PBS. Error bars represent the standard deviation from n = 2 independent experiments.
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Page 9 of 12which act via STAT1 signal transduction [17]. These data
suggest that the balance between pSTAT1 and pSTAT3
may influence cellular responsiveness to immunostimula-
tory cytokines and ultimately immune-mediated tumor
regression [17,40]. Data from this report also shows that
FLLL32 inhibited IL-6 induced STAT3 phosphorylation
within PBMCs. Of note, elevated levels of IL 6 are associ-
ated with poor prognosis in melanoma, and contribute to
the generation of immunosuppressive lymphoid cell pop-
ulations [41]. Finally, our studies indicate that FLLL32-
mediated inhibition of STAT3 does not alter production
of granzyme b or IFN γ by NK cells from normal donors
when cultured with K562 targets, or their viability when
cultured with IL-2. These properties are of importance
based on recent murine studies showing the Jak2 inhibi-
tor WP1193 can augment immunotherapy with IFN-α
[42], and STAT3 siRNA-CpG oligodeoxynucleotides can
elicit anti-tumor immune responses [43]. Together these
data suggest that STAT3 pathway inhibition could be
investigated further as a potential means by which to
overcome immune tolerance and augment responsive-
ness to standard or experimental immune-based thera-
pies.
Despite its improved STAT3 specificity, the FLLL32
analog retains some structural properties of its parent
compound, curcumin which as expected, limit its solubil-
ity and bioavailability (data not shown). Therefore, our
group is pursuing additional structural modifications or
Figure 5 FLLL32 inhibited IL 6 signaling but did not modulate IFN-γ or IL 2 induced signaling in PBMCs. PBMCs from healthy donors were pre-
treated for 16 hours with FLLL32 and subsequently treated with (A) IL 6 (0.1 ng/mL) or (B) IFN-γ (10 ng/mL) for 15 minutes. pSTAT3 and pSTAT1 were 
evaluated by immunoblot analysis. (C) The expression of the IFN-γ-stimulated gene, IRF1 was evaluated by Real Time PCR following a 1 hour pre-treat-
ment with FLLL32 and subsequently stimulated with IFN-γ (10 ng/mL) or PBS for an additional 4 hours. Real Time PCR data were expressed as fold 
change versus DMSO-pre-treated cells stimulated with PBS. Data were normalized to 18s rRNA levels. (D) PBMCs were pre-treated for 16 hours and 
subsequently treated with 8 nM IL 2 for 15 minutes. IL 2-induced pSTAT5 was evaluated by immunoblot analysis. All data are representative of PBMCs 
from two separate healthy donors.
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Page 10 of 12formulation approaches to further improve upon the bio-
availability of this small molecule, in light of its potent
and specific in vitro activity. The present results provide
evidence that the FLLL32 curcumin analog represents a
promising lead compound on which to base the further
development of STAT3-specific inhibitors against mela-
noma. The ability of FLLL32 to specifically inhibit the
STAT3 pathway while retaining the cellular response to
cytokines with anti-tumor activity is a particular advan-
tage that will be optimized in future pre-clinical studies.
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